Clinical trials: Temozolomide, completed
Ganglioneuroblastoma, Recurrent Neuroblastoma
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment.
- Trial name
- NCT01767194
- Testing
- Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 157 sites in United States, Australia and 3 more
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme of Brain
Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma
Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to standard postoperative radiation therapy…
- Trial name
- GLIO-XS15 (NCT04842513)
- Testing
- Multipeptide plus XS15
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Tuebingen
Gastrinoma, Glucagonoma
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
The purpose of this research is to evaluate the effectiveness and safety of a combination of capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor
- Trial name
- NCT01525082
- Testing
- Capecitabine, Temozolomide, Bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Shaheen Shagufta
Glioblastoma, Gliosarcoma
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate…
- Trial name
- NCT00613028
- Testing
- Temo + Avastin, VP-16 + Avastin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Adult Glioblastoma
Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Glioblastomas are extremely resistant to treatment, including radiotherapy and/or chemotherapy. Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation…
- Trial name
- GLYRad (NCT02364206)
- Testing
- LY2228820, Temozolomide, radiotherapy
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Centre Jean Perrin
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with recurrent…
- Trial name
- NCT00003304
- Testing
- temozolomide
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 29 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non Small Cell Lung Cancer, CNS Progression
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
This trial is testing two novel combinations (temozolomide plus osimertinib OR temozolomide plus lorlatinib) which have not been evaluated in clinical trials. Thus, the exact benefits of these novel combinations are unclear.
- Trial name
- NCT04541407
- Testing
- Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Colorado, Denver
Astrocytoma
TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
- Trial name
- NCT03032484
- Testing
- Bevacizumab, TVB-2640
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma.
- Trial name
- NCT03463265
- Testing
- nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aadi Bioscience, Inc.
Glioma, Anaplastic Astrocytoma
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches.
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT03072134
- Testing
- Neural stem cells loaded with an oncolytic adenovirus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme
A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
This is a Phase II, national, multicenter, open-label, non-comparative study to investigate the efficacy and safety of bevacizumab and temozolomide in patients with recurrent glioblastoma multiforme (GBM) after a first treatment…
- Trial name
- NCT01115491
- Testing
- bevacizumab [Avastin], temozolomide
- Where
- 8 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor Cancers
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.
- Trial name
- NCT01193140
- Testing
- veliparib, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Abbott
Glioblastoma, Gliosarcoma
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase I/II trial studies the side effects and how well atezolizumab works in combination with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma.
- Trial name
- NCT03174197
- Testing
- Atezolizumab, Radiation Therapy, Temozolomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Open-label, non-randomized, parallel assignment, phase 2 trial assessing the safety and efficacy of distinct temozolomide treatment regimens for patients with AML and poor prognosis
- Trial name
- NCT00611247
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Bruno C. Medeiros
Lung Diseases, Cancer
Combination Paclitaxel, Carboplatin and Temozolomide
The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to…
- Trial name
- NCT00249964
- Testing
- Combination Treatment - Cohort 1, Combination Treatment - Cohort 2, Combination Treatment - Cohort 3
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Recurrent Glioblastoma
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM.
- Trial name
- NCT03034135
- Testing
- Disulfiram/Copper, Temozolomide (TMZ)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cantex Pharmaceuticals
Glioblastoma Multiforme
Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients
The aim of this study is to establish FET-PET as an additional therapy assessment parameter in patients diagnosed with a glioblastoma multiforme receiving radiochemotherapy and adjuvant chemotherapy after previous resection or…
- Trial name
- NCT01089868
- Where
- 3 sites in Germany
- Volunteers
- 79 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Malignant Melanoma
A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy
This is the phase II, single-arm, single-center study assessing the efficacy of weekly docetaxel plus carboplatin in second-line treatment of malignant melanoma (unresectable or metastatic) who has failed dacarbazine or…
- Trial name
- NCT02223884
- Testing
- docetaxel 35mg/m2, Carboplatin AUC3
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Glioblastoma Multiforme
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00262730
- Testing
- poly ICLC, temozolomide, radiation therapy
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins